$1.16
−7.20%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.27
From 52W high−44.76%
Volume87564.00
Market cap$37.64M
P/E (TTM)—
P/S (TTM)2.0x
Div yield—
Key dataOct 19, 2026
Open
$1.27
From 52W high
−44.76%
Volume
87564.00
Market cap
$37.64M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
P/E (TTM)
—
RSI (14)
42.0
MomentumView details →
1D Return
−7.20%
YTD Return
+8.01%
SummaryUpdated Mar 1, 2026
Celularity Inc. (NASDAQ:CELU) is a clinical-stage biotechnology company founded in 2016 and headquartered in Florham Park, New Jersey. The company went public in August 2019 and specializes in developing innovative cell therapies derived from placental tissue. Celularity operates at the intersection of regenerative medicine and immunotherapy, focusing on creating "off-the-shelf" allogeneic cell treatments that can be used across multiple patients without the need for personalized manufacturing. The company has evolved from its initial focus on placental-derived therapies to encompass a broader portfolio including cell banking services and commercialized wound care products.
Similar companies
Latest newsMore news →
Celularity highlighted Fontaine Vitale as a strategic partner ahead of Fontaine Vitale's planned Q1 2027 opening in Bali, creating potential new revenue opportunities in Asia-Pacific regenerative medicine.19d agoCelularity Inc. appointed Naveen Jain to its Board of Directors, succeeding Diane Parks, who resigned.20d agoCelularity Inc and certain subsidiaries granted a collateral agent a continuing first-priority security interest in substantially all of their assets to secure the notes.21d ago